Xlife Sciences AG represents a strong commitment to innovation, integrity, and excellence. As a leading company in the life sciences sector, Xlife Sciences AG is dedicated to delivering cutting-edge solutions that positively impact various industries. With a focus on scientific advancements and sustainable growth, Xlife Sciences AG aims to improve the quality of life through its research, development, and commercialization activities. By fostering collaboration and embracing a forward-thinking approach, Xlife Sciences AG strives to create value for its stakeholders and make a meaningful difference in the field of life sciences.

Xlife Sciences AG is primarily present in Switzerland and Germany.

Xlife Sciences AG has achieved several significant milestones in its journey. The company has successfully developed and launched innovative biotechnological solutions that have revolutionized the healthcare industry. With a strong focus on research and development, Xlife Sciences AG has contributed to breakthrough discoveries in the field of life sciences. Additionally, the company has established key partnerships with renowned institutions and companies, allowing for further advancements in its cutting-edge technology. These milestones demonstrate Xlife Sciences AG's commitment to scientific excellence and its dedication to improving lives through transformative solutions.

Xlife Sciences AG is a leading biotechnology company specializing in the discovery and development of innovative therapies for various diseases. Founded in [year], Xlife Sciences AG has a rich history of pioneering research and development in the field of life sciences. The company focuses on leveraging its expertise and cutting-edge technologies to address unmet medical needs. Xlife Sciences AG has a diverse portfolio of promising drug candidates and strategic collaborations with renowned research institutions. With a strong commitment to improving global health, Xlife Sciences AG continues to drive advancements in biotechnology and contribute to the future of medicine.

The main competitors of Xlife Sciences AG in the market are companies such as ABC Biotech, XYZ Pharmaceutical, and LMN Life Sciences.

Xlife Sciences AG is primarily active in the biotechnology and life sciences industries.

The business model of Xlife Sciences AG is focused on identifying and investing in promising life science technologies and partnering with leading experts and entrepreneurs to bring innovative therapies and solutions to market. Xlife Sciences AG aims to create value by leveraging its extensive network and expertise in the life sciences sector to identify and support promising start-ups and early-stage companies. By providing both financial and strategic support, Xlife Sciences AG is committed to driving innovation and making a positive impact in the healthcare industry. The company aims to capitalize on emerging trends and advancements in life sciences to deliver sustainable growth and value for its investors.

Xlife Sciences P/E suhe on −65,07.

Xlife Sciences KUV on 125,15.

AlleAktien kvaliteediskoor ettevõttele Xlife Sciences on 4/10.

oodatud Xlife Sciences käive on 1,79 mln. CHF.

oodatud Xlife Sciences kasum on −3,43 mln. CHF.

The Xlife Sciences AG is a Swiss company specializing in the development of innovative diagnostics and therapeutics. The business model is based on identifying promising new substances and developing them into marketable products. The Xlife Sciences AG collaborates closely with research institutions, experts, and industry partners to identify innovative and promising molecular targets and translate them into potential diagnostics and therapeutics. The company utilizes a combination of state-of-the-art technologies, such as artificial intelligence and proprietary databases. The company is divided into three divisions: diagnostics, therapy, and technology. The diagnostics division focuses on the development of molecular test systems for early disease detection or monitoring therapy outcomes. This includes tests for severe lung and respiratory diseases, as well as blood tests for monitoring oncology patients. In the therapy division, Xlife Sciences AG is dedicated to developing novel treatment methods for serious and chronic diseases, particularly rare but highly severe conditions like SMA or Parkinson's disease. The company adopts a personalized approach based on individual molecular characteristics of the patient. The technology division of Xlife Sciences AG is involved in the development and commercialization of innovative diagnostic and therapeutic technologies. This includes a focus on scaling the automated processing of samples, improving test procedures through the use of artificial intelligence, and technologies for the treatment of chronic diseases. In collaboration with its partners, Xlife Sciences AG conducts research and development of new substances and seeks medical approvals. Additionally, the company collaborates with selected industry partners for product distribution. The products provided by Xlife Sciences AG target a wide range of customers in the medical and scientific fields. The aim is to cover as many customers as possible within their respective application areas and achieve promising results. Thanks to the diverse application areas of their products and the comprehensive expertise of the company, Xlife Sciences AG is an important partner for many companies, research institutions, and clinics worldwide. In summary, the business model of Xlife Sciences AG is based on the development of innovative diagnostics and therapeutics that are based on the molecular characteristics of the patient. The company works with partners from the scientific and industrial sectors to help identify and develop new substances. The products target a broad audience and cover a variety of application areas. As a leading innovator in this field, Xlife Sciences AG continuously relies on new technologies and expertise in the diagnosis and therapy of severe and chronic diseases.

Xlife Sciences maksab dividendi 0 CHF, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Xlife Sciences jaoks arvutada või ettevõte ei maksa dividende välja.

Xlife Sciences ISIN on CH0461929603.

Xlife Sciences WKN on A2PK6Z.

Xlife Sciences tähis on XLS.SW.

Viimase 12 kuu jooksul maksis Xlife Sciences dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Xlife Sciences tõenäoliselt dividendi summas 0 CHF.

Xlife Sciences praegune dividenditootlus on .

Xlife Sciences maksab kvartaalset dividendi. See makstakse välja kuudel .

Xlife Sciences maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 CHF. See vastab dividenditootlusele 0 %.

Xlife Sciences on liigitatud sektorisse 'Tervis'.

Viimase Xlife Sciences dividendide saamiseks 23.9.2024 suuruses 0 CHF pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 23.9.2024.

Viimane dividendimakse toimus 23.9.2024.

Aastal 2023 maksis Xlife Sciences 0 CHF dividende.

Xlife Sciences dividendid makstakse välja CHF.